MRNS Marinus Pharmaceuticals
- 1.440
- 0.0000.00%
- 1.440
- 0.000-0.03%
Marinus Pharmaceuticals News
Marinus Pharma Analyst Ratings
Marinus Pharma Analyst Ratings
Maintaining Buy Rating on Marinus Pharmaceuticals: Confidence in Research and Strategic Financial Health
Marinus Pharma Analyst Ratings
Buy Rating Affirmed for Marinus Pharmaceuticals With Promising Outlook for Ganaxolone in RSE Treatment
Marinus Pharma Analyst Ratings
Marinus Pharmaceuticals Earns Buy Rating From Analyst on Strong Sales and Promising Pipeline
Marinus Pharma Analyst Ratings
Optimistic Buy Rating for Marinus Pharmaceuticals Based on Promising Clinical Trials and NDA Potential
Buy Rating Affirmed for Marinus Pharmaceuticals Amid Strong Q4 Sales and Promising Clinical Trials
RBC Raises Price Target on Marinus Pharmaceuticals to $24 From $21, Keeps Outperform Rating
Marinus Pharma Analyst Ratings
Hold Rating on Marinus Pharmaceuticals: Delays, Opportunities, and Challenges in Clinical Trials
Truist Securities Maintains Buy on Marinus Pharma, Lowers Price Target to $25
Marinus Pharma Analyst Ratings
Marinus Pharmaceuticals Receives Buy Rating: Strong Q3 Results, Promising Therapeutic Programs, and Global Access Initiatives Drive Optimism
Cantor Fitzgerald Reiterates Overweight on Marinus Pharma, Maintains $28 Price Target
Marinus Pharmaceuticals' Prospective Growth Driven by Ganaxolone's Potential: An Analysis of Brian Skorney's Buy Rating
RBC Lifts Price Target on Marinus Pharmaceuticals to $21 From $20, Keeps Outperform Rating, Speculative Risk Qualifier
Marinus Pharmaceuticals: Promising Clinical and Financial Progress Leads to Buy Rating
Analysis
Price Target
No Data
